. 2021 Aug 31;10(18):6456–6467. doi: 10.1002/cam4.4158

TABLE 3.

Interactions of menopause status with BMI and breast density^a

	ER/PR+HER2−				TNBC				ER/PR+HER2+				ER/PR−HER2+
	HR	95% CI	p‐value	p‐interaction	HR	95% CI	p‐value	p‐interaction	HR	95% CI	p‐value	p‐interaction	HR	95% CI	p‐value	p‐interaction
BMI interaction
Premenopausal	N = 872 cases			<0.001	N = 86 cases			0.795	N = 132 cases			0.101	N = 49 cases			0.403
25–29 versus <25	1.22^*	1.04–1.44	0.013		1.49	0.90–2.47	0.124		1.41	0.95–2.11	0.091		0.82	0.41–1.66	0.573
≥30 versus <25	1.22^*	1.01–1.48	0.044		1.42	0.78–2.60	0.253		1.31	0.80–2.14	0.283		0.82	0.35–1.90	0.646
Postmenopausal	N = 1830 cases				N = 178 cases				N = 178 cases				N = 69 cases
25–29 versus <25	1.36^*	1.21–1.53	<0.001		1.49^*	1.03–2.01	0.036		1.04	0.71–1.53	0.838		0.97	0.52–1.79	0.910
≥30 versus <25	1.69^*	1.50–1.91	<0.001		1.20	0.80–1.81	0.383		1.85^*	1.27–2.69	0.001		1.64	0.89–3.01	0.113
Density interaction^b
Premenopausal	N = 942 cases			<0.001	N = 96 cases			0.019	N = 143 cases			0.907	N = 50 cases			0.723
Dense versus non‐dense	2.11^*	1.76–2.53	<0.001		2.84^*	1.61–5.04	<0.001		1.62^*	1.04–2.50	0.031		1.91	0.87–4.22	0.109
Postmenopausal	N = 1848 cases				N = 196 cases				N = 197 cases				N = 75 cases
Dense versus non‐dense	1.47^*	1.34–1.62	<0.001		1.38^*	1.00–1.03	0.042		1.98^*	1.45–2.71	<0.001		2.14^*	1.29–3.58	0.003

Abbreviations: BMI, body mass index; ER/PR, estrogen receptor/progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple‐negative breast cancer.

^{^a}

All models additionally adjusted for age, race, prior biopsy, atypical hyperplasia, age at menarche, age a first birth, and family history. Patients missing data on BMI or breast density were excluded from models assessing these interactions.

^{^b}

Non‐dense breasts comprise BI‐RADS A and B density categories. Dense breasts comprise the BI‐RADS C and D density categories.

p < 0.05.